Latest news with #UltraClear
Yahoo
5 days ago
- Business
- Yahoo
Acclaro Medical secures $23m in Series B funding for skin laser technologies
Acclaro Medical has completed a Series B funding round, raising $23m, to spur the growth of its flagship products, UltraClear and AuraLux, and facilitate the company's global market expansion. Accelmed Partners spearheaded the funding round, which also received support from the current investor, 3E Bioventures Capital. Acclaro Medical co-founder and CEO Helen Fang said: "This funding empowers us to continue our strong growth and realise our vision of improving the quality of life for people of all skin colours and all ages worldwide." UltraClear comprises a 2,910nm cold ablative fibre laser that leverages 3DIntelliPulse technology and offers enhanced safety across all types of skin. Cleared by the US Food and Drug Administration (FDA), UltraClear operates by vaporising the skin's damaged outer layers and heating the underlying layers with controlled thermal energy, promoting the growth of new cells and boosting elastin and collagen production. According to Acclaro Medical, the laser's cold beams aid in the removal of damaged epidermal cells, reducing side effects and pain. Its beam quality facilitates consistent resurfacing outcomes, akin to an advanced form of exfoliation. Alongside UltraClear, the company's AuraLux laser utilises the exclusive Cool Pulse technology. This expansion of the product line aims to enhance accessibility for providers and their patients. Acclaro Medical co-founder and president Shlomo Assa said: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-ageing solutions for healthier and younger-looking skin. 'It greatly enables us to accelerate product development, expand our team, and reach more customers globally." In 2022, Acclaro Corporation introduced the UltraClear laser technology system in the US. "Acclaro Medical secures $23m in Series B funding for skin laser technologies" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Cision Canada
6 days ago
- Business
- Cision Canada
Acclaro Medical Raises $23 Million in Series B Funding Led by Accelmed Partners to Advance Groundbreaking 2910 nm Fiber Laser Technology
Accelmed $20 Million Investment with 3E Bioventures Capital Funding of $3 Million to Drive Innovation, Clinical Expansion, and Global Market Growth SMITHFIELD, R.I., May 29, 2025 /CNW/ -- Acclaro Medical, a pioneering medical technology company focused on developing cutting-edge solutions that improve patient care and redefine medical practices, proudly announces the successful completion of its Series B funding round. Led by Accelmed Partners with participation by existing investor 3E Bioventures Capital, the combined funding of $23 million marks a pivotal milestone in the company's journey to fulfill unmet aesthetic needs through its innovative 2910 nm fiber laser solution and other disruptive technologies. This capital infusion will help Acclaro accelerate the growth of its flagship products, UltraClear ® and AuraLux ™ and expedite global market expansion while advancing development of new trailblazing products in its pipeline. Acclaro Medical's UltraClear fiber laser is recognized by leading aesthetic professionals as a breakthrough in Total Skin Health that treats multiple skin layers to help reverse the signs of aging and gravity. The first of its kind 2910 nm cold ablative fiber laser, powered by proprietary 3DIntelliPulse ™ technology, delivers: "The funding is a testament to our unstoppable team and tremendous progress Acclaro has made in a very short duration." Post this Unparalleled clinical efficacy Superior patient experiences Unmatched versatility Significantly improved safety for all skin types, including previously high-risk skin-of-color patients. Its precision-engineered capabilities make it the ideal choice for practitioners seeking transformative results with minimal downtime, reduced patient discomfort and speedy healing. Complementing UltraClear, the AuraLux laser leverages the same exclusive Cool Pulse ™ technology and broadens accessibility for aesthetic providers and their patients while maintaining Acclaro's hallmark quality. "Securing this Series B investment is a powerful testament to our unstoppable team and the tremendous progress that Acclaro has made in a very short period of time," said Acclaro Medical CEO and Co-founder Helen Fang. "This funding empowers us to continue our strong growth and realize our vision of improving the quality of life for people of all skin colors and all ages worldwide." Shlomo Assa, President and co-founder of Acclaro Medical, noted: "We are thrilled to have the support of Accelmed as we expand our global and domestic footprint. This Series B funding is a strong vote of confidence in our mission to bring UltraClear and AuraLux to more people pursuing anti-aging solutions for healthier and younger-looking skin. It greatly enables us to accelerate product development, expand our team, and reach more customers globally – And we're just getting started!" The Series B funding will allow Acclaro Medical to leverage decades of Accelmed's operational and financial expertise, alongside 3E Bioventures' disciplined efficiency. Acclaro Medical is poised to execute its strategic plans and realize its vision of revolutionizing the aesthetic industry. These efforts will further cement the company's position as a leader in providing innovative, patient-centered skin health solutions. "Acclaro's unique cold laser fiber technology constitutes a game changer in laser aesthetics with the possibility for aesthetic practices to safely treat all skin types for all major indications using only one device," stated Daniel Cohen, Accelmed's venture partner with extensive experience leading successful Medtech & Biotech investments over the last 20 years. "Accelmed Partners is thrilled to lead this round of financing and accompany Acclaro' s management in this fantastic journey." About Acclaro Medical Founded in 2018 by world-class industry experts, Acclaro Medical is committed to developing, innovating and bringing to market game-changing solutions to address today's unmet medical, aesthetic and surgical practice needs. With a relentless commitment to innovation and a team of dedicated professionals, Acclaro Medical continues to push the boundaries and drive positive change in the aesthetic medical industry. Its proprietary 3DMIRACL ™ and Laser Coring ™ skin rejuvenation treatments are valued for offering unrivaled aesthetic results complemented by high patient comfort, rapid healing and utmost safety across all skin types. For more information, please visit About Accelmed Partners Accelmed, a leader in healthcare technology investing, is renowned for its private equity approach to a sector traditionally dominated by venture and early-stage growth firms. Its team of experienced industry veterans and company builders work closely as a trusted partner with portfolio management to improve operations, upgrade product portfolios, and strengthen commercial organizations. Accelmed's support and resources are designed to help portfolio companies like Acclaro Medical elevate its technology and achieve enduring success. The investment firm currently manages over $630 million of equity capital. For more information, please visit
Medscape
7 days ago
- Health
- Medscape
Full Ablation Making a Comeback in Energy-Based Medicine
ORLANDO, Fla. — For years, fully ablative laser skin resurfacing — in which the epidermis is removed using carbon dioxide or erbium lasers — fell out of favor among energy-based medicine specialists and their patients because of long recovery times and the need for general anesthesia. Fractional ablative laser resurfacing, a less invasive procedure that makes tiny holes in the epidermis and leaves surrounding skin intact, became more popular, along with nonablative collagen-stimulating treatments. But at The American Society for Laser Medicine and Surgery (ASLMS) 2025 Annual Meeting, held from April 24 to 26, several presenters spoke about a 'resurgence' of the full ablation approach. They cited two reasons: First, results from fractional treatments have not been as dramatic or durable as hoped for, especially in older patients, and second, newer laser technologies are allowing for ablation to be performed without general anesthesia and with healing times closer to those seen with less-invasive treatments. Echoing many of his colleagues at the conference, Oculofacial Surgeon Brian Biesman, MD, of Vanderbilt University, who is in private practice in Nashville, Tennessee, said that in recent years he has returned to performing fully ablative procedures after having given them a rest. 'The moment for me was when I saw a patient who I knew I had seen several years before,' Biesman said in an interview. 'I didn't remember what [procedure] I had done, and I thought she needed laser resurfacing. I opened her chart and realized that I had done fractional ablative resurfacing on her 3 years before. That was when I decided that for what we put people through, they need to have a better result than this 3 years later. I decided to get back to more aggressive approaches.' Dermatologic Surgeon Thomas Rohrer, MD, who is in private practice in Chestnut Hill, Massachusetts, said in an interview that to treat deeper lines, especially in certain parts of the face, 'we're coming to a consensus that we need that more aggressive treatment. That's why you're seeing a lot of talks this year about fully ablative devices. But with that comes the risks associated with it and the downtime.' Ablative Therapy With Less Pain and Shorter Recovery While ablative procedures using time-tested technologies — CO2 and erbium lasers — are also making a comeback, Rohrer and other specialists pointed to a newer device that they described as a game changer: The UltraClear 2910 nm cold ablative fractional laser, cleared by the US Food and Drug Administration in 2022 to treat photoaging, wrinkles, and acne scars, which has since seen its indications expanded to include some types of pigmented lesions. The device can be used on fractional ablative or fully ablative settings. It does not heat tissue the way traditional ablative lasers do. This results in reduced pain and shorter recovery time, and offers additional protection against hypo- and hyper-pigmentation, a key concern with darker skin types. The 2910 nm laser 'has really revitalized our resurfacing practice in patients aged 50 to 80,' said Paul Friedman, MD, who is in private practice in Houston, 'because of the patient comfort and the quicker recovery process,' which can be as little as a week compared with a month or more for other technologies. Ablative procedures with the 2910 nm laser usually require only 'topical anesthesia and occasional nitrous oxide,' Friedman said at the meeting. 'Prior to this technology, with our traditional resurfacing modalities, we found it more efficient to bring in an anesthesiologist. But obviously there is hesitance from patients about this.' Suzanne Kilmer, MD, a dermatologist at the University of California, Davis, California, who is also in private practice in Sacramento, California, and a widely recognized expert on full ablation, said that she was still getting to know the device. She has yet to use the 2910 nm laser for a fully ablative procedure, she said, sticking to its fractional settings. 'I use it in conjunction with the traditional erbium and CO2 lasers,' Kilmer said in an interview, adding that she is fine with going slow for now. 'There always is a learning curve with devices,' she cautioned. 'And you're learning on risky procedures.' Preventing and Mitigating Complications Full ablation 'is a great procedure — there's nothing else like it,' Kilmer continued. But unlike with fractional treatments, it also means that 'you've taken off the whole top of the skin. There's a huge open wound. You've completely disrupted the dermal-epidermal junction.' During different seminars at the conference, experts offered strategies for avoiding treatment-related complications, including hypo- and hyper-pigmentation, scarring, and infections. They spoke about selecting the patients who are likely to comply with demanding aftercare protocols, highlighting how they rescued cases in which patients did not. And they shared horror stories of patients who went kayaking 3 days after ablative treatment, accidentally vomited on their wounds, who developed severe erythema or scarring, or developed serious infections despite the use of antiviral and antibiotic prophylaxis. With some of these complications, practitioners acknowledged that there is little consensus on how they should be managed. Jacqueline Watchmaker, MD, a dermatologist in private practice in Scottsdale, Arizona, reviewed the case of a patient who developed a severe bacterial infection following ablation because of noncompliance with aftercare recommendations. It is important to know how soon infections are likely to appear, Watchmaker said, and to be aware of signs — especially pain that increases over days. It's also important to select patients carefully for their likelihood of complying, she added. Other presenters discussed ways to improve compliance, such as by making video tutorials. Dermatologist Arisa Ortiz, MD, director of Laser and Cosmetic Dermatology, at UC San Diego Health, San Diego, and the past president of ASLMS, warned that even with antibiotic and antiviral prophylaxis, patients can develop breakthrough infections requiring emergency treatment. The right type of antibiotic prophylaxis remains controversial in fully ablative resurfacing, she noted. Any apparent infections should be cultured before treating them and systemic infections, requiring hospital treatment, can occur. Biesman, in his comments, agreed that antibiotic prophylaxis remains a controversial topic with ablative resurfacing. 'The argument from infectious disease is that you don't need antibiotic prophylaxis,' he told the conference, but in practice it is standard. And while many clinicians use cefalexin, which does not prevent infections from methicillin-resistant Staphylococcus aureus , or MRSA, 'you really need to think about MRSA coverage' when prescribing an antibiotic, he said.
